Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway

Clinical Cancer Research (2011) - Comments
pubmed: 21106726 doi: 10.1158/1078-0432.ccr-10-2572 issn: 1078-0432 issn: 1557-3265

Giorgio Zauli, Rebecca Voltan, Raffaella Bosco, Elisabetta Melloni, Sandra Marmiroli, Gian Matteo Rigolin, Antonio Cuneo, Paola Secchiero